Hanmi Pharmaceuticals, Co. Ltd. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 79 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Markets Direct's, 'Hanmi Pharmaceuticals, Co. Ltd. - Product Pipeline Review - 2014', provides an overview of the Hanmi Pharmaceuticals, Co. Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Hanmi Pharmaceuticals, Co. Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Hanmi Pharmaceuticals, Co. Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Hanmi Pharmaceuticals, Co. Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Hanmi Pharmaceuticals, Co. Ltd.'s pipeline products

Reasons to buy

- Evaluate Hanmi Pharmaceuticals, Co. Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Hanmi Pharmaceuticals, Co. Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Hanmi Pharmaceuticals, Co. Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Hanmi Pharmaceuticals, Co. Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Hanmi Pharmaceuticals, Co. Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Hanmi Pharmaceuticals, Co. Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Hanmi Pharmaceuticals, Co. Ltd. Snapshot 8
Hanmi Pharmaceuticals, Co. Ltd. Overview 8
Key Information 8
Key Facts 8
Hanmi Pharmaceuticals, Co. Ltd. - Research and Development Overview 9
Key Therapeutic Areas 9
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Partnered Products/Combination Treatment Modalities 17
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products Glance 18
Hanmi Pharmaceuticals, Co. Ltd. - Late Stage Pipeline Products 18
Phase III Products/Combination Treatment Modalities 18
Hanmi Pharmaceuticals, Co. Ltd. - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
Hanmi Pharmaceuticals, Co. Ltd. - Early Stage Pipeline Products 21
Preclinical Products/Combination Treatment Modalities 21
Discovery Products/Combination Treatment Modalities 22
Hanmi Pharmaceuticals, Co. Ltd. - Drug Profiles 23
(montelukast sodium + levocetirizine dihydrochloride) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
(paclitaxel + HM30181A) 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
HCP-1105 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
HCP-1302 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
HCP-1305 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
HCP-1306 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
HCP-1401 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
sildenafil citrate IMD 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
(aceclofenac + eperisone) 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
(Bacillus subtilis + mosapride + Streptococcus faecium) 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
HM-10460A 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
HM-10560A 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
HM-10660A 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HM-11260C 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
poziotinib 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
KX-01 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
(ambroxol + levodropropizine) 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(fluticasone propionate + salmeterol) 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
(irinotecan hydrochloride + HM30181A) 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
(metformin + rosuvastatin calcium) 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
epoetin alfa Long Acting 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
HCP-0904 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
HCP-1007 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
HCP-1303 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
HIP-0901 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
HM-12525A 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
HM-61713 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
HM-71224 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
insulin human Long Acting 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
(rosuvastatin calcium + fenofibric acid) 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
(tamsulosin + dutasteride) 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
exenatide + insulin human 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
HM-12160B 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
HM-12470 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
HM-47000 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
HM-95573 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
HM-12260B 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Analysis 62
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Target 62
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Route of Administration 65
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Molecule Type 66
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Mechanism of Action 67
Hanmi Pharmaceuticals, Co. Ltd. - Recent Pipeline Updates 70
Hanmi Pharmaceuticals, Co. Ltd. - Dormant Projects 76
Hanmi Pharmaceuticals, Co. Ltd. - Locations And Subsidiaries 77
Head Office 77
Other Locations & Subsidiaries 77
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 79
Disclaimer 79

List of Tables
Hanmi Pharmaceuticals, Co. Ltd., Key Information 8
Hanmi Pharmaceuticals, Co. Ltd., Key Facts 8
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Indication, 2014 11
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Stage of Development, 2014 13
Hanmi Pharmaceuticals, Co. Ltd. - Monotherapy Products in Pipeline, 2014 14
Hanmi Pharmaceuticals, Co. Ltd. - Combination Treatment Modalities in Pipeline, 2014 15
Hanmi Pharmaceuticals, Co. Ltd. - Partnered Products in Pipeline, 2014 16
Hanmi Pharmaceuticals, Co. Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 17
Hanmi Pharmaceuticals, Co. Ltd. - Phase III, 2014 18
Hanmi Pharmaceuticals, Co. Ltd. - Phase II, 2014 19
Hanmi Pharmaceuticals, Co. Ltd. - Phase I, 2014 20
Hanmi Pharmaceuticals, Co. Ltd. - Preclinical, 2014 21
Hanmi Pharmaceuticals, Co. Ltd. - Discovery, 2014 22
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Target, 2014 63
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Route of Administration, 2014 65
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Molecule Type, 2014 66
Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Mechanism of Action, 2014 68
Hanmi Pharmaceuticals, Co. Ltd. - Recent Pipeline Updates, 2014 70
Hanmi Pharmaceuticals, Co. Ltd. - Dormant Developmental Projects,2014 76
Hanmi Pharmaceuticals, Co. Ltd., Subsidiaries 77